INPP5D | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
B cell	33 studies	33% ± 13%	Explore
natural killer cell	32 studies	29% ± 10%	Explore
macrophage	20 studies	34% ± 19%	Explore
memory B cell	19 studies	30% ± 9%	Explore
naive B cell	17 studies	29% ± 7%	Explore
CD8-positive, alpha-beta T cell	16 studies	24% ± 9%	Explore
T cell	15 studies	26% ± 9%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	33% ± 9%	Explore
CD16-negative, CD56-bright natural killer cell, human	14 studies	32% ± 10%	Explore
mature NK T cell	14 studies	24% ± 9%	Explore
endothelial cell	14 studies	30% ± 13%	Explore
gamma-delta T cell	13 studies	24% ± 6%	Explore
regulatory T cell	13 studies	23% ± 8%	Explore
microglial cell	12 studies	58% ± 21%	Explore
CD4-positive, alpha-beta T cell	11 studies	25% ± 10%	Explore
non-classical monocyte	11 studies	27% ± 14%	Explore
myeloid cell	11 studies	32% ± 13%	Explore
mucosal invariant T cell	10 studies	24% ± 9%	Explore
CD8-positive, alpha-beta memory T cell	9 studies	24% ± 4%	Explore
classical monocyte	9 studies	25% ± 10%	Explore
conventional dendritic cell	9 studies	27% ± 12%	Explore
monocyte	9 studies	30% ± 15%	Explore
dendritic cell	9 studies	43% ± 16%	Explore
effector memory CD8-positive, alpha-beta T cell	8 studies	28% ± 10%	Explore
mast cell	8 studies	26% ± 11%	Explore
plasmacytoid dendritic cell	7 studies	24% ± 9%	Explore
leukocyte	6 studies	42% ± 25%	Explore
innate lymphoid cell	6 studies	28% ± 9%	Explore
hematopoietic precursor cell	5 studies	26% ± 9%	Explore
hematopoietic stem cell	5 studies	24% ± 9%	Explore
lymphocyte	5 studies	46% ± 23%	Explore
CD4-positive, alpha-beta memory T cell	5 studies	19% ± 3%	Explore
precursor B cell	4 studies	26% ± 4%	Explore
pro-B cell	4 studies	22% ± 2%	Explore
immature B cell	4 studies	24% ± 2%	Explore
endothelial cell of lymphatic vessel	4 studies	26% ± 4%	Explore
abnormal cell	4 studies	24% ± 4%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	3 studies	28% ± 9%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	3 studies	17% ± 2%	Explore
plasma cell	3 studies	23% ± 8%	Explore
mononuclear phagocyte	3 studies	28% ± 9%	Explore
germinal center B cell	3 studies	32% ± 7%	Explore
endothelial cell of vascular tree	3 studies	30% ± 19%	Explore
alveolar macrophage	3 studies	22% ± 4%	Explore
group 3 innate lymphoid cell	3 studies	25% ± 4%	Explore
brush cell	3 studies	37% ± 13%	Explore
double negative thymocyte	3 studies	23% ± 5%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	3 studies	30% ± 10%	Explore
astrocyte	3 studies	30% ± 10%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	11 studies	23% ± 9%	Explore
bone marrow	3 studies	21% ± 4%	Explore
brain	3 studies	28% ± 11%	Explore
lymph node	3 studies	22% ± 5%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	100%	5357.47	578 / 578	86%	13.27	992 / 1155
breast	99%	2587.89	456 / 459	86%	11.37	967 / 1118
intestine	90%	3443.69	871 / 966	94%	23.66	498 / 527
kidney	94%	1769.24	84 / 89	90%	17.11	810 / 901
thymus	96%	1815.37	624 / 653	86%	15.18	523 / 605
uterus	100%	1906.11	170 / 170	76%	9.61	348 / 459
stomach	81%	954.13	289 / 359	94%	23.89	270 / 286
bladder	90%	1982.14	19 / 21	83%	16.65	419 / 504
brain	72%	1139.34	1892 / 2642	98%	19.90	690 / 705
esophagus	93%	1236.61	1347 / 1445	76%	12.60	139 / 183
prostate	99%	2562.60	242 / 245	63%	5.23	315 / 502
skin	71%	1105.69	1291 / 1809	67%	11.48	314 / 472
adrenal gland	88%	1064.49	226 / 258	50%	3.80	115 / 230
pancreas	16%	157.12	52 / 328	90%	16.32	161 / 178
ovary	43%	501.18	78 / 180	63%	6.86	269 / 430
lymph node	0%	0	0 / 0	100%	130.58	29 / 29
peripheral blood	100%	19912.03	929 / 929	0%	0	0 / 0
spleen	100%	19695.24	241 / 241	0%	0	0 / 0
ureter	0%	0	0 / 0	100%	7.38	1 / 1
adipose	100%	3108.22	1203 / 1204	0%	0	0 / 0
liver	53%	506.58	119 / 226	40%	3.77	162 / 406
tonsil	0%	0	0 / 0	87%	19.03	39 / 45
blood vessel	75%	1234.36	996 / 1335	0%	0	0 / 0
heart	70%	812.30	602 / 861	0%	0	0 / 0
muscle	30%	246.75	241 / 803	0%	0	0 / 0
eye	0%	0	0 / 0	20%	1.76	16 / 80
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0045671	Biological process	negative regulation of osteoclast differentiation
GO_0045779	Biological process	negative regulation of bone resorption
GO_0032715	Biological process	negative regulation of interleukin-6 production
GO_0009968	Biological process	negative regulation of signal transduction
GO_0008340	Biological process	determination of adult lifespan
GO_0007165	Biological process	signal transduction
GO_0050777	Biological process	negative regulation of immune response
GO_0006796	Biological process	phosphate-containing compound metabolic process
GO_0046856	Biological process	phosphatidylinositol dephosphorylation
GO_0050852	Biological process	T cell receptor signaling pathway
GO_0045579	Biological process	positive regulation of B cell differentiation
GO_0050776	Biological process	regulation of immune response
GO_0035556	Biological process	intracellular signal transduction
GO_0045656	Biological process	negative regulation of monocyte differentiation
GO_0016064	Biological process	immunoglobulin mediated immune response
GO_0045659	Biological process	negative regulation of neutrophil differentiation
GO_0045648	Biological process	positive regulation of erythrocyte differentiation
GO_0006915	Biological process	apoptotic process
GO_0043065	Biological process	positive regulation of apoptotic process
GO_0030889	Biological process	negative regulation of B cell proliferation
GO_0006661	Biological process	phosphatidylinositol biosynthetic process
GO_0005856	Cellular component	cytoskeleton
GO_0005886	Cellular component	plasma membrane
GO_0045121	Cellular component	membrane raft
GO_0005829	Cellular component	cytosol
GO_0052658	Molecular function	inositol-1,4,5-trisphosphate 5-phosphatase activity
GO_0034485	Molecular function	phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase activity
GO_0004439	Molecular function	phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity
GO_0016314	Molecular function	phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity
GO_0052659	Molecular function	inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity
GO_0004445	Molecular function	inositol-polyphosphate 5-phosphatase activity
GO_0005515	Molecular function	protein binding
GO_0017124	Molecular function	SH3 domain binding

IV. Literature review

[source]

Gene name	INPP5D
Protein name	Inositol polyphosphate-5-phosphatase D (Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1) Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (EC 3.1.3.86) (Inositol polyphosphate-5-phosphatase D) (EC 3.1.3.56) (Inositol polyphosphate-5-phosphatase of 145 kDa) (SIP-145) (Phosphatidylinositol 4,5-bisphosphate 5-phosphatase) (EC 3.1.3.36) (SH2 domain-containing inositol 5'-phosphatase 1) (SH2 domain-containing inositol phosphatase 1) (SHIP-1) (p150Ship) (hp51CN)
Synonyms	SHIP1 SHIP
Description	FUNCTION: Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways . Able also to hydrolyzes the 5-phosphate of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P3) and inositol 1,3,4,5-tetrakisphosphate . Acts as a negative regulator of B-cell antigen receptor signaling. Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Acts as a negative regulator of myeloid cell proliferation/survival and chemotaxis, mast cell degranulation, immune cells homeostasis, integrin alpha-IIb/beta-3 signaling in platelets and JNK signaling in B-cells. Regulates proliferation of osteoclast precursors, macrophage programming, phagocytosis and activation and is required for endotoxin tolerance. Involved in the control of cell-cell junctions, CD32a signaling in neutrophils and modulation of EGF-induced phospholipase C activity . Key regulator of neutrophil migration, by governing the formation of the leading edge and polarization required for chemotaxis. Modulates FCGR3/CD16-mediated cytotoxicity in NK cells. Mediates the activin/TGF-beta-induced apoptosis through its Smad-dependent expression. .
Accessions	ENST00000627169 R4GMN8 ENST00000445964.6 [Q92835-1] ENST00000628842 H7C403 ENST00000359570.9 [Q92835-2] ENST00000630854.3 [Q92835-1] ENST00000415617.5 ENST00000491070.1 ENST00000417661.1 Q92835 H0Y5Q9 ENST00000629761.2 [Q92835-2] ENST00000629792

INPP5D report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review